Leukemia

The addition of bortezomib to chemotherapy significantly improved survival outcomes among children and young adults with T-cell lymphoblastic lymphoma, according to phase 3 study results published in Journal of Clinical Oncology.

Approximately 14% of adults with acute myeloid leukemia harbored germline pathogenic or likely pathogenic variants in a hematologic malignancy predisposition gene, according to study results published in Blood.

A phase 2/phase 3 study assessed intramuscular asparaginase Erwinia chrysanthemi (recombinant)-rywn for patients with acute lymphoblastic leukemia or lymphoblastic lymphoma who developed hypersensitivity to E. coli-derived L-asparaginase.

CHICAGO — Asciminib continued to confer superior efficacy and better safety and tolerability than bosutinib among patients with chronic-phase chronic myeloid leukemia, according to study results presented during ASCO Annual Meeting.

CHICAGO — The addition of daratumumab to chemotherapy improved outcomes among younger patients with relapsed or refractory T-cell acute lymphoblastic leukemia, study results showed.

The FDA granted fast track designation to mocravimod in combination with allogeneic hematopoietic stem cell transplantation for post-remission therapy of acute myeloid leukemia.

The FDA approved ivosidenib tablets in combination with azacitidine for previously untreated IDH1-mutated acute myeloid leukemia.

Treatment with a hypomethylating agent may activate or upregulate SALL4, an oncogene that plays a key role in myelodysplastic syndrome and other cancers, according to study results published in The New England Journal of Medicine.

First responders to the World Trade Center had higher rates of clonal hematopoiesis-associated mutations than firefighters not exposed to the dust, gases and potential carcinogens at the site, according to a study in Nature Medicine.

The FDA approved azacitidine for treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia.